Injected and infused nicotinamide adenine dinucleotide (NAD+) raises blood concentrations of the coenzyme, but human trials have not shown that this rise produces clinical improvements, and no study has established an evidence-based dosing schedule.

At Longevity Benchmark, we review the clinical and regulatory literature behind commercial wellness therapies so readers can separate measurable laboratory changes from clinic promotional claims.

Every frequency recommendation quoted by a commercial provider reflects clinical convention rather than validated trial data. Patients considering parenteral therapy must evaluate the specific delivery route, the pharmacokinetic reality of rapid blood clearance, and the documented quality record of unapproved compounded formulations.

The Verdict

Direct NAD+ administration reliably elevates circulating plasma concentrations, yet current human evidence stops at blood chemistry without verifying downstream clinical outcomes. No published clinical trial establishes an optimal dose, administration frequency, or treatment duration for healthy adults or disease populations.

This therapy is unsuited for individuals expecting validated prevention of biological aging or those seeking treatment for diagnosed medical conditions. Our perspective would change if a double-blind, randomised controlled trial demonstrated that parenteral NAD+ improves validated functional biomarkers or clinical endpoints over oral precursors in a pre-registered human cohort.

Evidence for Injected NAD+ and Clinical Claims

Injected and infused nicotinamide adenine dinucleotide (NAD+) elevates circulating coenzyme concentrations in human blood, but published clinical trials have not demonstrated that this elevation treats medical conditions or extends human longevity.

Nicotinamide adenine dinucleotide serves as a fundamental coenzyme in cellular energy transfer and metabolic signalling. Commercial clinics frequently market intravenous infusions and subcutaneous shots for anti-aging, chronic fatigue, addiction recovery, and general vitality. These clinical claims extrapolate cellular biochemistry and rodent models into therapeutic promises that lack confirmation in controlled human trials.

No prospective human trial demonstrates that injecting the intact molecule produces superior clinical outcomes compared to standard medical care or basic lifestyle interventions. What the scientific literature does confirm is that parenteral delivery bypasses digestive degradation to increase circulating plasma metabolites. Whether that systemic increase alters intracellular pools in target organs remains an open biological question.

Patients receiving these therapies at elective wellness practices should recognize that they are participating in an unvalidated commercial protocol rather than a standard medical treatment. Readers exploring clinic models can review our analysis of what a longevity clinic provides to evaluate clinical governance standards.

Differences Across Delivery Routes

The primary differences among intramuscular injections, subcutaneous injections, and intravenous infusions centre on fluid volume, administration speed, systemic absorption rates, and clinical supervision requirements.

Intravenous (IV) infusions deliver NAD+ dissolved in normal saline directly into the bloodstream over several hours. This method requires venous cannulation and professional monitoring in a medical office or infusion suite. Because large amounts of the compound enter circulation continuously, providers typically control the infusion rate to reduce acute patient discomfort.

Intramuscular (IM) injections involve administering a concentrated dose directly into skeletal muscle tissue, typically targeting the deltoid or gluteal muscles. The volume a muscle can take in one injection is limited, which caps the total amount of active compound delivered in a single visit. The exact volume varies by clinic. Intramuscular delivery provides slower systemic absorption than an intravenous drip because the drug must diffuse from muscle vascular beds into general circulation.

Subcutaneous (SC) injections deliver small volumes of the compound into the fatty layer directly beneath the skin, commonly in the abdomen or upper thigh. Patients often self-administer subcutaneous shots at home using small insulin-gauge needles after receiving a prescription from a licensed practitioner. Subcutaneous absorption is gradual, but local tissue irritation and injection-site burning remain common patient complaints.

Alternative non-oral delivery options also exist outside of direct needle injections. For a complete analysis of transdermal technology, read our review of iontophoretic NAD+ patches.

Human Pharmacokinetic Evidence from the Grant Infusion Study

A landmark human pharmacokinetic study revealed that intravenous infusion of NAD+ produces a 398% increase in circulating plasma concentrations only after an initial two-hour period of rapid systemic clearance.

In a pilot pharmacokinetic trial published by Grant and colleagues, researchers examined the plasma and urine metabolome of 11 male participants aged 30 to 55 years during a constant intravenous infusion. The cohort included eight test participants receiving the active compound and three control participants receiving a placebo saline drip.

The clinical protocol delivered 750 mg of NAD+ dissolved in normal saline over a continuous six-hour period. This protocol maintained an average infusion rate of approximately 2 milligrams per minute, which equals an infusion rate of 3 micromoles per minute.

Researchers observed that plasma concentrations of NAD+ and its direct metabolic breakdown products did not change during the first two hours of infusion. During this initial window, the infused molecule was rapidly and completely removed from the vascular compartment. The authors noted that this clearance points to rapid tissue uptake, cellular internalisation, or immediate enzymatic degradation in peripheral capillary beds.

After the two-hour mark, plasma concentrations climbed steadily until reaching a 398% elevation above baseline at the six-hour mark. Urinary excretion analysis revealed that participants eliminated intact NAD+ and methyl nicotinamide in their urine, but did not excrete excess nicotinamide. The investigators recorded no adverse events throughout the six-hour infusion, but they emphasized that measuring plasma elevation does not prove intracellular accumulation within target organs.

Absence of Evidence-Based Frequency Protocols

No published human trial has evaluated or validated a specific dosing schedule for NAD+ injections in healthy adults or clinical cohorts.

Patients contacting wellness clinics encounter divergent scheduling recommendations, ranging from daily loading infusions over four days to weekly intramuscular injections or monthly maintenance drips. These administration patterns originate entirely from proprietary commercial protocols rather than peer-reviewed clinical research. Phase II dose-ranging trials that establish safe and optimal frequency intervals for pharmaceutical agents have never been conducted for injectable NAD+ formulations.

Because scientific schedules do not exist, providers quote frequencies based on commercial precedent and operational convenience. Some clinics advise high-frequency loading regimens to saturate blood concentrations quickly, while others suggest lower monthly intervals to improve patient compliance and reduce appointment friction. Neither approach rests on empirical pharmacokinetic data showing how long elevated intracellular concentrations persist after administration.

Before committing to a recurring protocol, patients should ask their clinician what measurable biomarker or clinical endpoint determines their recommended re-dosing interval. If a clinic cannot supply objective criteria for its schedule, patients should evaluate the proposed frequency as an unverified commercial protocol. Our overview of longevity clinic pricing details how recurring infusion programs affect total healthcare expenditures.

Real-World Tolerability and Clinic Adverse Events

Real-world clinical data shows that rapid intravenous NAD+ administration produces frequent acute physical symptoms, including moderate to severe gastrointestinal cramping and chest tightness.

A retrospective tolerability review evaluated electronic medical records from a commercial wellness clinic comparing intravenous NAD+ against intravenous nicotinamide riboside (NR). The investigation examined six clients who received intravenous NAD+ and eight clients who received intravenous NR. Both groups received 500 mg of the respective compound diluted in 500 mL of normal saline administered on four continuous days.

The clinical records revealed distinct differences in administration time and patient discomfort. The mean infusion time for NAD+ was 97 plus or minus 56.33 minutes, whereas NR required only 37 plus or minus 13.08 minutes, representing a 60% reduction in total infusion duration. Slower administration was mandatory for the NAD+ group because rapid flow rates triggered intense physical reactions.

All six NAD+ clients experienced moderate to severe abdominal cramping, diarrhoea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure during their infusions. In contrast, five of the eight NR clients reported only minor tingling in the tongue, jaw, or arms, alongside mild cramping. Neither patient cohort exhibited clinically meaningful changes in liver enzymes or circulating inflammatory markers.

The authors of the clinic review noted significant study limitations that readers must weigh carefully. The analysis relied on a retrospective design, examined an extremely small patient cohort, lacked a randomised placebo control group, and was designed and executed by a commercial wellness clinic that possessed implicit commercial interests. For an exhaustive assessment of infusion reactions, consult our dedicated guide on NAD+ injection side effects.

Compounding Pharmacy Quality and the FDA Enforcement Record

Injectable NAD+ products distributed by wellness clinics are unapproved compounded preparations rather than pharmaceuticals evaluated under an approved Food and Drug Administration (FDA) new drug application (NDA).

Because no pharmaceutical manufacturer holds an approved NDA for an injectable NAD+ drug, commercial clinics source their vials from state-licensed compounding pharmacies. Compounded preparations are mixed, packaged, and sterilized by individual pharmacies to fill specific medical orders. They do not undergo the pre-market safety testing, efficacy verification, or continuous manufacturing inspections required for standard prescription medications.

Data extracted from the FDA enforcement database on 27 September 2026 demonstrates consistent quality control challenges across the compounding sector. The federal database recorded 14 separate recall actions for injectable nicotinamide adenine dinucleotide products between 2016 and 2025, originating from seven distinct compounding firms.

The federal agency classified 13 of the enforcement actions as Class II recalls and one as a Class I recall. Under federal regulatory definitions, a Class I recall designates a dangerous situation where there is a reasonable probability that exposure to the product will cause serious adverse health consequences or death. A Class II recall identifies a scenario where exposure may cause temporary or medically reversible health problems.

Ten of the 14 federal recalls were initiated due to a lack of sterility assurance or microbial contamination of sterile products. The single Class I enforcement action involved GenoGenix LLC regarding NAD+ for Injection at 100 mg/mL and 200 mg/mL concentrations in 10 mL multi-dose amber vials. The official reason for the GenoGenix LLC recall was microbial contamination of sterile products resulting from elevated endotoxin levels, with the recall initiated on 30 July 2025 and formally reported by the FDA on 15 October 2025.

These federal enforcement actions do not mean that every vial from a compounding pharmacy is contaminated. They do confirm that sterile compounding carries inherent microbiological risks that require stringent quality assurance. Patients considering injectable therapies should request a recent certificate of analysis verifying sterility and endotoxin testing directly from their administering clinician.

Injected NAD+ Compared to Oral Precursors

The fundamental pharmacological difference between injected NAD+ and oral supplements involves cellular transport mechanisms and systemic bioavailability.

Direct injections deliver intact coenzyme molecules into the blood or interstitial space, completely avoiding hepatic first-pass metabolism and gastrointestinal degradation. However, extracellular NAD+ cannot easily cross the plasma membranes of many mammalian cell types without first being broken down into smaller precursor molecules by cell-surface enzymes like CD73 and CD38.

Oral precursor supplements such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) rely on natural cellular salvage pathways to generate intracellular coenzymes. Oral precursors undergo extensive metabolism in the liver and gut microbiome before reaching systemic tissues, but they offer painless daily administration at a fraction of the cost of clinical injections.

Our comparison of NMN and NR covers the muscle-biopsy evidence: in Elhassan's three-week study of NR in older men, NAD+ metabolites in skeletal muscle rose without any matching change in mitochondrial bioenergetics. Our guide to how NAD+ functions inside cells sets out the biochemistry behind that result.

Frequently Asked Questions

What are NAD injections?

NAD injections are medical procedures that administer the coenzyme nicotinamide adenine dinucleotide directly into the body through a needle. They are delivered via intravenous infusions, intramuscular shots, or subcutaneous injections to bypass the gastrointestinal tract. Because there are no approved pharmaceutical brand-name products, these solutions are mixed by state-licensed compounding pharmacies for use in elective wellness clinics. Clinics promote them for energy metabolism, cellular health, and anti-aging, although human clinical outcome trials remain uncompleted.

Do NAD+ injections work?

Injected NAD+ reliably raises circulating blood levels of the coenzyme, but human trials have not confirmed that this biochemical change produces clinical health benefits. A pharmacokinetic trial showed a 398% increase in plasma NAD+ after six hours of continuous intravenous delivery. However, that trial only measured blood and urine metabolites without assessing physical performance, fatigue, disease progression, or longevity. The scientific record does not yet support claims that parenteral delivery treats medical conditions or reverses aging in humans.

Are NAD injections safe?

NAD injections carry documented acute side effects and quality control risks that patients must weigh carefully. During rapid intravenous infusions, patients frequently report moderate to severe abdominal cramping, nausea, vomiting, chest pressure, and throat pain due to acute vascular and smooth muscle reactions. Furthermore, because these products are unapproved compounded drugs, quality depends entirely on the compounding pharmacy. The FDA enforcement database records 14 recalls for injectable NAD+ between 2016 and 2025, ten of which involved sterility failures or endotoxin contamination.

How often do you need NAD injections?

No human clinical trial has established a validated dosing frequency or schedule for NAD+ injections. Commercial wellness clinics suggest diverse regimens, ranging from daily loading drips over several days to weekly intramuscular injections or monthly maintenance appointments. These frequencies represent commercial operational conventions rather than scientifically validated dosing schedules. Because rigorous phase II dose-finding studies do not exist, patients cannot determine an optimal administration interval based on current medical literature.

What is the difference between a NAD shot and a NAD IV drip?

The main differences involve administration volume, procedure time, and vascular delivery methods. An IV drip infuses a high dose of NAD+ diluted in 500 mL of normal saline over a period the published studies put at anywhere from roughly an hour and a half to six hours through a vein, which requires direct clinical supervision in an infusion clinic. A shot delivers a small, concentrated volume into muscle tissue or under the skin in a couple of minutes. Intravenous drips produce larger systemic exposure, but intramuscular and subcutaneous shots offer substantially greater convenience and lower procedure costs.

Are NAD injections better than oral NAD supplements?

Direct injections achieve higher immediate circulating blood concentrations by bypassing digestive degradation, but research has not shown that they produce better intracellular outcomes than oral supplements. Intact extracellular NAD+ cannot easily enter many cell types without first being broken down into precursor fragments at the cell membrane. Oral precursors like NMN and NR use natural salvage pathways to support intracellular synthesis without requiring needle sticks, clinical supervision, or the high expenses associated with compounding pharmacies. Neither delivery format has demonstrated superior long-term clinical outcomes in human comparative trials.

Are NAD+ injections FDA approved?

Injectable NAD+ products are not approved by the Food and Drug Administration. No commercial pharmaceutical company has submitted a new drug application demonstrating the safety and clinical efficacy of injectable NAD+ through standard phase III trials. Instead, these solutions are prepared as compounded medications by licensed compounding pharmacies under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded drugs do not undergo pre-market agency review for clinical efficacy, safety, or manufacturing consistency.

Related